Low peripheral blood viral HIV-2 RNA in individuals with high CD4 percentage differentiates HIV-2 from HIV-1 infection

Journal of Human Virology

Volumn 1, Issue 7, 1998, Pages 457-468

  Berry, Neil ^a,e   Ariyoshi, Koya ^b,d   Jaffar, Shabbar ^c   Sabally, Sehu ^b   Corrah, Tumani ^b   Tedder, Richard ^a   Whittle, Hilton ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^e NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

HIV 1; HIV 2; Pathogenesis; Viral load; West Africa

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2;

CD4 ANTIGEN; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BLOOD; CD4 LYMPHOCYTE COUNT; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; GAMBIA; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; IMMUNOLOGY; ISOLATION AND PURIFICATION; MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PROVIRUS; VIROLOGY; VIRULENCE; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIGENS, CD4; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; GAMBIA; HIV-1; HIV-2; HUMANS; LEUKOCYTES, MONONUCLEAR; POLYMERASE CHAIN REACTION; PROVIRUSES; RNA, VIRAL; VIRAL LOAD; VIRULENCE;

EID: 0032195713     PISSN: 10909508     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Clavel F, Guetard D, Drun-Vezinet F, et al. Isolation of a new human retrovirus from West African patients with AIDS. Science 1986;223:343-346.
2. Romieu I, Marlink R, Kanki P, M'Boup S, Essex M. HIV-2 link to AIDS in West Africa. J AIDS 1990;3:220-230.
3. DeCock K, Odehouri K, Colebunders RL, et al. A comparison of HIV-1 and HIV-2 infections in hospitalised patients in Abidjan, Cote d'Ivoire. AIDS 1990;4:443-448.
4. Naucler A, Albino P, Andersson S, et al. Clinical and immunological follow-up of previously hospitalised HIV-2 seropositive patients in Bissau, Guinea-Bissau. Scand J Infect Dis 1992;24:725-731.
5. Poulsen A-G, Aaby P, Frederiksen K, Molbak K, Dias F, Lauritzen E. Prevalence and mortality from human immunodeficiency virus type 2 in Bissau. Lancet 1989;1:827-831.
6. Ricard D, Wilkins A, N'Gum PT, et al. The effects of HIV-2 infection in a rural area of Guinea Bissau. AIDS 1994;8: 977-982.
7. Marlink R, Kanki P, Thior I, et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 1994;265:1587-1590.
8. Whittle H, Morris J, Todd J, et al. HIV-2-infected patients survive longer than HIV-1-infected patients. AIDS 1994; 8:1617-1620.
9. Kanki PJ, Travers K, M'Boup S, et al. Slower heterosexual spread of HIV-2 than HIV-1. Lancet 1994;343:943-946.
10. Poulsen A-G, Aaby P, Larsen O, et al. 9-year HIV-2-associated mortality in an urban community in Bissau, West Africa. Lancet 1997;349;911-914.
11. Adjorolo-Johnson G, DeCock KM, Ekpini E, et al. Prospective comparison of mother-to-child transmission of HIV-1 and HIV-2 in Abidjan, Ivory Coast. JAMA 1994;272:402-466.
12. + lymphopaenia in HIV type 2-infected individuals. AIDS Res Hum Ret 1994;10:1031-1037.
13. Ariyoshi K, Berry NJ, Wilkins A, et al. A community-based study of HIV-2 proviral load in a rural village in West Africa. J Infect Dis 1996;173:245-248.
14. Simon F, Matheron S, Tamalet C, et al. Cellular and plasma viral load in patients infected with HIV-2. AIDS 1993;7:1411-1417.
15. Albert J, Bottiger B, Biberfeld G, Fenyo E. Replicative capacity of HIV-2, like HIV-1, correlates with severity of immunodeficiency. AIDS 1990;4:291-295.
16. Schulz T, Whitby D, Hoad J, Corrah T, Whittle H, Weiss R. Biological and molecular variability of human immunodeficiency virus type 2 isolates from The Gambia. J Virol 1990;64:5177-5182.
17. Gao F, Yue L, Pappas P, et al. Human infection by genetically diverse SIVsm-related HIV-2 in West Africa. Nature 1992;358:495-499.
18. Piatek MJ, Saag MS, Yang LC, et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993;259:1749-1754.
19. Michael NL, Vahey M, Burke DS, Redfield RR. Viral DNA and mRNA expression correlate with the stage of human immunodeficiency virus (HIV) type 1 infection in humans: evidence for viral replication in all stages of HIV disease. J Virol 1992;66:310-316.
20. Saksela K, Stevens C, Rubinstein P, Taylor PE, Baltimore D. HIV-1 messenger RNA in peripheral blood mononuclear cells as an early marker of risk for progression to AIDS. Ann Intern Med 1995;123:641-648.
21. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-126.
22. Wei X, Gosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-122.
23. + T cells. AIDS 1997;11:1103-1110.
24. Mellors JW, Rinaldo CR, Gupta P, White R, Todd JA, Kingsley LA. Prognosis of HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272, 1167-1170.
25. Ariyoshi K, Cheingsong-Popov R, Wilkins A, Corrah T, Weber J, Whittle H. HIV-1 subtype B in West Africa. Lancet 1996;347:328.
26. + cells is faster in HIV-1 than in HIV-2 infection. J AIDS Hum Retroviruses 1997;6:327-332.
27. Bobkov A, Cheingsong-Popov R, Salminen M, et al. Complex mosaic structure of the partial envelope sequence from a Gambian HIV type 1 isolate. AIDS Res Hum Retroviruses 1996;12:169-171.
28. + T-cell determinations in persons with human immunodeficiency (HIV) infection. MMWR 1994;43(RR-3):1-21.
29. Boom R, Sol C, Salimans M, et al. Rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990;28:495-503.
30. World Health Organization. WHO network for HIV isolation and characterisation. AIDS Res Hum Retroviruses 1994;10:1359.
31. Whitby K, Garson JA. Optimisation and evaluation of a quantitative chemiluminescent polymerase chain reaction assay for hepatitis C virus RNA. J Virol Methods 1995; 51:75-88.
32. Rodrigo AG, Goracke PC, Rowhanian K, Mullins JI. Quantitation of target molecules from polymerase chain reaction-based limiting dilution assays. AIDS Res Hum Retroviruses 1997;13:737-742.
33. Armitage P, Berry G. Statistical methods in medical research. Oxford: Blackwell Science, 1994.
34. Arnold C, Barlow KL, Kaye S, Loveday C, Balfe P, Clewley JP. HIV type 1 sequence subtype G transmission from mother to infant: failure of variant sequence species to amplify in the Roche amplicor test. AIDS Res Hum Retroviruses 1995;11:999-1001.
35. Alaeus A, Lidman K, Sonnerborg A, Albert J. Subtype-specific problems with quantification of plasma HIV-1 RNA. AIDS 1997;11:859-865.
36. Coffin J. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995;267:483-489.
37. Chun T-W, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997;387:183-188.
38. Markovitz D, Smith M, Hilfinger J, Hannibal M, Petryniak B, Nabel G. Activation of the human immunodeficiency virus type 2 enhancer is dependent on purine box and (B regulatory elements. J Virol 1992;66:5479-5484.
39. Ning Xu X, Screaton GR, Gotch F, et al. Evasion of cytotoxic T lymphocyte (CTL) responses by nef-dependent induction of fas ligand (CD95L) expression on simian immunodeficiency virus-infected cells. J Exp Med 1997;186:7-15.
40. Sinclair E, Barbosa P, Feinberg MB. The nef gene products of both simian and human immunodeficiency viruses enhance virus infectivity and are functionally interchangeable. J Virol 1997;71:3641-3651.
41. Xiang Z, Ariyoshi K, Wilkins A, Dias F, Whittle H, Breuer J. HIV type 2 pathogenicity is not related to subtype in rural Guinea Bissau. AIDS Res Hum Retroviruses 1997; 13:501-505.
42. Nowak M, Anderson RM, McLean AR, Wolfs FW, Goudsmit J, May RM. Antigenic diversity thresholds and the development of AIDS. Science 1991;254:963-969.
43. Gotch F, McAdam SN, Allsopp CE, et al. Cytotoxic T cells in HIV-2 seropositive Gambians: identification of a virus-specific MHC-restricted peptide epitope. J Immunol 1993; 151:3361-3369.
44. Ariyoshi K, Cham F, Berry N, Corrah T, Whittle H. HIV-2-specific cytotoxic T-lymphocyte activity is inversely related to proviral load. AIDS 1995;9:555-559.
45. + cells from HIV-2-infected baboons control HIV replication. AIDS 1997;11:737-746.
46. Bjorling E, Scarlatti G, von Gegerfelt A, et al. Autologous neutralising antibodies prevail in HIV-2 but not in HIV-1 infection. Virology 1993;193:528-530.
47. Nowak M, Bangham CR. Population dynamics of immune responses to persistent viruses. Science 1996;272:74-79.
48. Vesanen M, Stevens CE, Taylor PT, Rubinstein P, Saksela K. Stability in controlling viral replication identifies non-progressors as a distinct subgroup among human immunodeficiency virus type 1-infected persons. J Virol 1996; 70:9035-9040.
49. Hirsch VM, Fuerst TR, Sutter G, et al. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunisation with a trivalent SIV vaccine virus Ankara. J Virol 1996;70:3741-3752.
50. Watson A, Ranchalis J, Travis B, et al. Plasma viraemia in macaques infected with simian immunodeficiency virus: plasma viral load early in infection predicts survival. J Virol 1997;71:284-290.